Reslizumab is associated with significant clinical benefit and is well tolerated in patients with refractory asthma (RA) and elevated blood eosinophil counts, concludes a study published in BMJ Open Respiratory Research.
The post-hoc analysis included a subpopulation of patients with RA from two previously published multi-centre, double-blind, randomised, placebo-controlled phase 3 trials (NCT01287039 and NCT01285323). Of 306 patients who met the criteria for RA, 145 received reslizumab and 161 received placebo.
In patients with RA, compared to placebo, reslizumab was associated with a 59 per cent reduction in the adjusted mean rate of clinical asthma exacerbations (CAEs) requiring hospitalisation and/or use of systemic corticosteroids (SCS) for ≥3 days.
Improvements in lung function (change from baseline in FEV1) were 158 mL greater with reslizumab than placebo.
Compared with placebo, reslizumab was associated with greater patient-reported asthma control, asthma-related quality of life and asthma symptoms in the population with RA.
The observed safety profiles of reslizumab and placebo were similar.
The study is the first to report on the efficacy of reslizumab in patients with refractory asthma and eosinophilia. The findings suggest that the treatment is beneficial for refractory patients, similar to results for the general population of patients with asthma and eosinophilia.